|View printer-friendly version|
|BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer|
"We are very excited to have Dr. Kern join our company as we advance our ALS clinical program and prepare for the start of Phase 3 testing of NurOwn®," said
"I am thrilled to join BrainStorm and advance the Phase 3 program for NurOwn to seek an effective solution for ALS patients and their families," said Dr. Kern. "I am confident that BrainStorm will become the world leader in adult stem cell therapies for neurodegenerative disorders."
Dr. Kern is an influential leader, consensus builder, and strategic advisor with expertise translating science into global solutions for patient care. He was most recently Senior Vice President and Head of Worldwide Medical at Biogen, where he was a powerful contributor to Biogen's reputation as a world leader in biopharmaceutical innovation. He helped define the company's therapeutic area and medical/scientific strategies for Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, Parkinson's, neuro-degeneration, and hemophilia.
From 2011 to 2014, Dr. Kern was Vice President and Head of Neuroscience Medical Unit at
From 2006 to 2011, Dr. Kern was Global Medical Director of
Previously, he was a Neurologist Consultant at
Dr. Kern studied in the undergraduate Neurophysiology program at
Gilenya® is a registered trademark of
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-strengthens-management-team-with-appointment-of-ralph-z-kern-md-mhsc-as-chief-operating-officer-and-chief-medical-officer-300418226.html